A Nitric Oxide-Donor Furoxan Moiety Improves the Efficacy of Edaravone against Early Renal Dysfunction and Injury Evoked by Ischemia/Reperfusion

Figure 2

Effects of EDV and NO-EDV on renal dysfunction evaluated on blood and urine parameters. Serum urea (a), creatinine (b), creatinine clearance (c), urine flow (d), and urinary NGAL (e) and NAG (f) levels were measured after sham operation (sham) or renal ischemia-reperfusion injury (vehicle). Further groups of rats received EDV (1.2–30 μmol/kg, i.v.) or NO-EDV (0.3–6 μmol/kg, i.v.) at the beginning of reperfusion and again after 30 min reperfusion. Data are expressed as mean ± S.E.M. < 0.05 versus vehicle.

(a)

(b)

(c)

(d)

(e)

(f)